Lantheus Holdings Inc (LNTH)
NASDAQ:LNTH
Want to see LNTH full AI Analyst Report?
LNTH Stock Chart & Stats
$83.82
-$2.32(-2.39%)
At close: 4:00 PM EST
$83.82
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $103.89
Previous CloseN/A
Volume177.90K
Average Volume (3M)943.82K
Market Cap
$6.71B
Enterprise Value$6.21B
Total Cash (Recent Filing)$498.58M
Total Debt (Recent Filing)$803.00K
Price to Earnings (P/E)10.4
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,106,080
10 Day Avg. Volume1,123,005
30 Day Avg. Volume943,821
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda16.78
Forecast
1Y Price Target
$103.25Price Target Upside23.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.33
Revenue Forecast (FY)$1.47B
Bulls Say, Bears Say
Bulls Say
Manufacturing CapacityNew formulation expands batch capacity and manufacturing efficiency, improving supply readiness and supporting a commercial rollout that could drive meaningful revenue growth.
Regulatory ClarityRegulatory review issues tied to manufacturing rather than clinical safety reduce concern about product safety and support expectations that manufacturing fixes could enable approval.
Reimbursement ProspectsApproval of a new fluorinated PSMA PET agent increases the likelihood of transitional pass-through reimbursement, which could improve pricing and product mix and help stabilize the flagship franchise as a competitor's temporary reimbursement expires.
Bears Say
Delayed Pipeline BenefitsRecent approvals and pipeline assets are unlikely to produce meaningful near-term revenue, creating a setup period without immediate sales benefit and increasing execution risk.
Near-term Revenue HeadwindsRevenue guidance implies a decline driven by increased competition for core products, putting pressure on near-term sales and limiting upside.
Pricing Pressure And Volume DeclineOngoing pricing erosion is expected to outweigh modest volume gains, contributing to declining flagship product sales and lower imaging dose volumes that heighten revenue risk.
Lantheus News
LNTH FAQ
What was Lantheus Holdings Inc’s price range in the past 12 months?
Lantheus Holdings Inc lowest stock price was $47.25 and its highest was $103.89 in the past 12 months.
What is Lantheus Holdings Inc’s market cap?
Lantheus Holdings Inc’s market cap is $6.71B.
When is Lantheus Holdings Inc’s upcoming earnings report date?
Lantheus Holdings Inc’s upcoming earnings report date is Jul 30, 2026 which is in 66 days.
How were Lantheus Holdings Inc’s earnings last quarter?
Lantheus Holdings Inc released its earnings results on May 07, 2026. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.229 by $0.231.
Is Lantheus Holdings Inc overvalued?
According to Wall Street analysts Lantheus Holdings Inc’s price is currently Undervalued.
Does Lantheus Holdings Inc pay dividends?
Lantheus Holdings Inc does not currently pay dividends.
What is Lantheus Holdings Inc’s EPS estimate?
Lantheus Holdings Inc’s EPS estimate is 1.29.
How many shares outstanding does Lantheus Holdings Inc have?
Lantheus Holdings Inc has 65,106,080 shares outstanding.
What happened to Lantheus Holdings Inc’s price movement after its last earnings report?
Lantheus Holdings Inc reported an EPS of $1.46 in its last earnings report, beating expectations of $1.229. Following the earnings report the stock price went up 5.63%.
Which hedge fund is a major shareholder of Lantheus Holdings Inc?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.25 (23.18% Upside)
$103.25 (23.18% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 80.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.79%
12-Months-Change
Fundamentals
Return on Equity
24.33%
Trailing 12-Months
Asset Growth
14.18%
Trailing 12-Months
Company Description
Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$103.25
▲(23.18% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
12.63% Insiders
34.97% Mutual Funds
12.75% Other Institutional Investors
10.89% Public Companies and
Individual Investors